Healthcare Services

Night Blindness Treatment Market Analysis Through 2030 Focusing On Demand Trends And Growth Drivers

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Night Blindness Treatment Market Change Between 2026 And 2030?

The night blindness treatment market size has demonstrated significant expansion over recent years. It is anticipated to increase from $4.2 billion in 2025 to $4.46 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. The market’s historical growth can be attributed to the high prevalence of malnutrition, limited access to eye care services, growing awareness of vision disorders, an increasing geriatric population, and advancements in ophthalmic diagnostics.

The night blindness treatment market size is anticipated to experience robust expansion over the coming years, projected to reach $5.66 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This projected growth during the forecast period is attributable to increased investment in eye health initiatives, a growing demand for tailored treatments, the broadening scope of gene therapy applications, improvements in healthcare infrastructure, and more favorable reimbursement policies. Key trends expected within this period encompass the escalating prevalence of vitamin A deficiency, the wider adoption of early diagnostic methods, an increase in minimally invasive eye surgical procedures, the greater utilization of nutritional and preventive therapeutic approaches, and enhanced access to vision care services in emerging economies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18413&type=smp

What Key Growth Drivers Are Influencing The Night Blindness Treatment Market?

A growing incidence of cataracts is anticipated to drive the expansion of the night blindness treatment market in the future. This condition involves the clouding of the eye’s lens, resulting in diminished vision. Factors such as elevated exposure to ultraviolet (UV) light from the sun, smoking, and inadequate diet contribute to their formation. Cataracts impair the eye’s capacity to differentiate between varying light and dark tones, a function vital for effective night vision. Consequently, this reduced contrast sensitivity complicates navigation and object recognition in dimly lit settings. An illustrative example from May 2024, data from the Office for Health Improvement & Disparities, a UK-based government department, indicated that hospital admissions for cataract surgery in England surpassed 516,000 during the financial year ending 2023, representing 4,679 per 100,000 people. This marked a notable increase from the preceding year’s figure of 3,803 per 100,000. Hence, the rising incidence of cataracts is propelling the night blindness treatment market.

What Key Segment Areas Are Included In The Night Blindness Treatment Market Assessment?

The night blindness treatment market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Other Treatments

2) By Diagnosis: Blood Tests, Color Vision Testing, Pupil Light Reflex, Refraction, Retinal Exam, Electroretinogram (ERG), Other Diagnoses

3) By Symptom: Eye Pain, Cloudy Vision, Halos, Light Sensitivity, Distance Vision Problem, Other Symptoms

4) By End User: Clinic, Hospital, Other End Users

Subsegments:

1) By Medication: Vitamin A Supplements, Retinoid Therapy, Beta-Carotene Supplements, Anti-Glaucoma Medications

2) By Surgery: Cataract Surgery, Retinal Surgery, Corneal Transplantation, LASIK Surgery

3) By Other Treatments: Light Therapy, Gene Therapy, Low Vision Aids And Assistive Devices, Nutritional Therapy

Which Trends Are Expected To Shape The Night Blindness Treatment Market?

Leading companies in the Niemann-pick disease type C (NPC) treatment market are concentrating on developing innovative treatments, such as neuroprotective therapies, to slow the progression of the disease and improve patient outcomes. Neuroprotective therapies are interventions designed to shield the brain and nervous system from damage or degeneration, often with the goal of preserving neurological function in conditions like neurodegenerative diseases. For instance, in September 2024, IntraBio Inc., a US-based biopharmaceutical company, announced that AQNEURSA (levacetylleucine) received approval from the United States Food and Drug Administration (FDA), a US-based regulatory agency, making it the first stand-alone treatment for Niemann-Pick Disease Type C (NPC). This approval follows successful Phase III trial results, which showed significant neurological improvements in NPC patients within 12 weeks. AQNEURSA provides a much-needed treatment option for individuals impacted by this rare lysosomal storage disorder, affecting movement, cognition, and daily function. IntraBio also plans to explore AQNEURSA’s potential for treating other neurodegenerative and neurodevelopmental disorders.

Which Companies Are Influencing The Night Blindness Treatment Market?

Major companies operating in the night blindness treatment market are Johnson & Johnson Private Limited, Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc, Bausch Health Companies Inc, Cipla Inc, Nature’s Way, Garden of Life, Apellis Pharmaceuticals Inc, Solgar, Acucela Inc, Swanson Health Products, Astellas Pharma Inc, F. Hoffmann-La Roche Ltd, Applied Genetic Technologies Corp, MeiraGTx Holdings plc, GenSight Biologics, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Opthea Limited, Oxurion NV, EyePoint Pharmaceuticals Inc, Ocuphire Pharma Inc.

Access The Complete Night Blindness Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/night-blindness-treatment-global-market-report

What Is The Largest Regional Market In The Night Blindness Treatment Market?

North America was the largest region in the night blindness treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the night blindness treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Night Blindness Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=18413&type=smp

Browse Through More Reports Similar to the Global Night Blindness Treatment Market 2026, By The Business Research Company

Alpers Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/alpers-disease-treatment-global-market-report

Rare Inflammatory Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Rare Neurological Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795